Abstract
Objective: We aimed to perform a meta-analysis of randomized controlled trials (RCTs) to summarize the overall effect of tocilizumab on the risk of mortality among patients with coronavirus disease 2019 (COVID-19).
Methods: We systematically searched PubMed, Cochrane Central Register of Controlled Trials, Google Scholar, and medRxiv (preprint repository) databases (up to 7 January 2021). Pooled effect sizes with 95% confidence interval (CI) were generated using random-effects and inverse variance heterogeneity models. The risk of bias of the included RCTs was appraised using version 2 of the Cochrane risk-of-bias tool for randomized trials.
Results: Six RCTs were included: two trials with an overall low risk of bias and four trials had some concerns regarding the overall risk of bias. Our meta-analysis did not find significant mortality benefits with the use of tocilizumab among patients with COVID-19 relative to non-use of tocilizumab (pooled hazard ratio = 0.83; 95% CI 0.66-1.05, n = 2,057). Interestingly, the estimated effect of tocilizumab on the composite endpoint of requirement for mechanical ventilation and/or all-cause mortality indicated clinical benefits, with some evidence against our model hypothesis of no significant effect at the current sample size (pooled hazard ratio = 0.62; 95% CI 0.42-0.91, n = 749).
Conclusion: Despite no clear mortality benefits in hospitalized patients with COVID-19, tocilizumab appears to reduce the likelihood of progression to mechanical ventilation.
Keywords: Bias; COVID-19; Clinical trial; Mortality; Tocilizumab.
【저자키워드】 COVID-19, clinical trial, Mortality, Tocilizumab, bias, 【초록키워드】 Randomized controlled trial, coronavirus disease, Meta-analysis, Coronavirus disease 2019, clinical trial, Randomized controlled trials, Trial, mechanical ventilation, Tocilizumab, risk, progression, hospitalized patients, database, heterogeneity, RCT, controlled trials, clinical, Risk of bias, Patient, RCTs, Evidence, Hypothesis, Google Scholar, composite endpoint, randomized trials, Repository, Sample size, 95% CI, no significant effect, significant effect, 95% confidence interval, hazard ratio, clinical benefits, all-cause mortality, medRxiv, Version, effect size, random-effects, benefit, likelihood, indicated, appear, searched, hospitalized patient, reduce, Controlled, patients with COVID-19, random-effect, risk of bia, with COVID-19, 【제목키워드】 Randomized controlled trial, hospitalized patient,